<DOC>
	<DOCNO>NCT00985790</DOCNO>
	<brief_summary>The purpose present study assess immunogenicity safety vaccine GSK2321138A child .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline Biologicals ' Candidate Influenza Vaccine Healthy Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>For subject : Subjects investigator believe and/or Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . Written inform consent obtain subject/from LAR ( ) . For unprimed subject : A male female child age 18 47 month time first vaccination . Children influenza vaccine previous season . For primed subject study NCT00764790 : • Children receive Fluarix™ 111751 study NCT00764790 . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . History hypersensitivity vaccine . History allergy reaction likely exacerbate component vaccine . Planned administration/ administration vaccine foreseen study protocol period start one month end 28 day dose vaccine ( ) . Acute chronic clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . Acute disease time enrolment . History Guillain Barré syndrome within 6 week receipt prior inactivate influenza virus vaccine . Receipt another seasonal influenza vaccine outside study , current ( 20092010 ) flu season . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccination Inhaled topical steroid allow . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>Influenza</keyword>
</DOC>